获得批准对儿童进行罕见血液疾病治疗. Hemogenyx gets approval to test its rare blood disorder treatment in children.

药剂公司获得监管部门的批准,开始将儿科患者纳入其临床试验,以治疗一种罕见的血液疾病,这是扩大研究范围到年轻人群的关键步骤. Hemogenyx Pharmaceuticals has received regulatory approval to begin enrolling pediatric patients in its clinical trial for a potential treatment targeting a rare blood disorder, marking a key step in expanding the study’s scope to younger populations.